急性心肌梗死患者再灌注治疗后影响预后指标的研究进展

摘要

Acute myocardial infarction is a common diseases which can result serious public health problem. Since the 1980s of the 20th century, the launch of the reperfusion therapy (thrombolytic therapy and emergency PCI), protect the heart function in greatest degree, reduce the mortality signiifcantly. However, the post-AMI complications after reperfusion therapy for patients is the focus of attention in medical profession. Therefore, the study affect reperfusion therapy in patients with AMI prognosis and their timely treatment or preventive measures taken, to improve the quality of life of patients and long-term survival rate is particularly important. This article focuses on some biochemical indicators of prognosis of Roperfusion therapies in Acute Myocardial Infarction Patients.%急性心肌梗死（acute myocardial infarction，AMI）是急性、持续性缺血、缺氧所引起的心肌坏死，对人类健康的危害极大。20世纪80年代以来，再灌注治疗（静脉溶栓和急诊PCI）的开展最大程度的保护了心功能，明显降低了病死率[1]。但是，给予再灌注治疗后的AMI患者后期所出现的并发症是目前医学界关注的焦点[2-3]。因此，研究影响AMI患者再灌注治疗预后的指标并采取相应治疗措施对患者的预后显得非常重要。本文着重讨论影响急性心肌梗死患者再灌注治疗预后的一些相关生化指标。